Related Experiment Videos
[Cardiovascular diseases in heterozygote beta-thalassemia subjects]
M Gallerani1, M Faggioli, L Martinelli
1U.S.L. n. 33, Codigoro, Ospedale San Camillo di Comacchio, Divisione Medica.
Insights
Individuals with beta thalassemia trait show fewer cardiovascular events like heart attacks and strokes. However, they experience these events later in life and have fewer risk factors, including high cholesterol.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Genetics
Context:
- Beta thalassemia trait is common in certain populations.
- Cardiovascular disease (CVD) risk factors and outcomes are influenced by genetic factors.
- Understanding CVD in specific genetic backgrounds is crucial for public health.
Purpose:
- To analyze cardiovascular disease incidence and recurrence in individuals with beta thalassemia trait.
- To investigate the relationship between beta thalassemia trait and atherogenic risk factors.
- To compare cardiovascular event patterns in subjects with and without beta thalassemia trait.
Summary:
- A 44-month analysis revealed a lower incidence of acute myocardial infarctions and strokes in subjects with beta thalassemia trait.
- Despite lower overall incidence, these subjects experienced infarctions later in middle age.
- A notable finding was the reduced prevalence of atherogenic risk factors, particularly hyperlipoproteinemias, in the thalassemic trait group.
Impact:
- Provides insights into the protective cardiovascular effects of beta thalassemia trait.
- Highlights potential differences in CVD progression and risk factor profiles.
- Informs clinical risk assessment and management strategies for individuals with beta thalassemia trait.
Abstract:
Forty-four months analysis of cardiovascular diseases in a population with a high incidence of beta thalassemia trait is reported. A lower incidence of acute myocardiac infarctions, strokes, and their recurrence was observed in subjects with thalassemic trait; however they present more infarctions in later middle age and a lower incidence of atherogenic risk factors, specially hyperlipoproteinemias.